Sector
PharmaceuticalsOpen
₹9,300.5Prev. Close
₹9,410.5Turnover(Lac.)
₹11,542.41Day's High
₹9,460Day's Low
₹8,79552 Week's High
₹10,69152 Week's Low
₹6,069.7Book Value
₹331.06Face Value
₹2Mkt Cap (₹ Cr.)
22,177.5P/E
126.86EPS
70.02Divi. Yield
021 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
16 Jul 2024
12:00 AM
AGM
Announcement Date: 16 Jul, 2024
27 May 2024
12:00 AM
Dividend
Dividend Amount: 24
Record Date: 05 Jul, 2024
Here are some of the stocks that may see significant price movement today: ITD Cementation, Premier Energies, AstraZeneca, etc.
The approval is for two dosing forms: 120 mg/2.4 ml and 500 mg/10 ml.
The company may import the powder form of sodium zirconium cyclosilicate for preparation of oral suspension as Lokelma in 5 g and 10 g formulation.
As per the reported property consultants, the company has issued a global mandate for selecting candidates for the said land deal.
It is used with Durvalumab to treat advanced or recurrent endometrial cancer in patients whose disease has not progressed after first-line treatment.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 706.92 | 583.69 | 506.39 | 451.17 |
Net Worth | 711.92 | 588.69 | 511.39 | 456.17 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 805.6 | 813.56 | 831.81 | 571 |
yoy growth (%) | -0.97 | -2.19 | 45.67 | 5.01 |
Raw materials | -311.96 | -294.95 | -305.23 | -181.09 |
As % of sales | 38.72 | 36.25 | 36.69 | 31.71 |
Employee costs | -230.21 | -219.54 | -216.7 | -153.53 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 83.04 | 127.09 | 113.97 | 43.8 |
Depreciation | -16.95 | -20.13 | -18.58 | -14.74 |
Tax paid | -21.44 | -33.79 | -41.76 | -17.89 |
Working capital | 57.86 | 101.15 | 103.65 | 52.76 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -0.97 | -2.19 | 45.67 | 5.01 |
Op profit growth | -36.38 | 12.23 | 160.74 | 25.31 |
EBIT growth | -34.47 | 11.35 | 162.8 | 23.38 |
Net profit growth | -33.97 | 29.2 | 178.69 | 29.22 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Narayan K Seshadri
Non-Exec. & Independent Dir.
Revathy Ashok
Non-Exec. & Independent Dir.
Shilpa Divekar Nirula
Managing Director
Sanjeev Panchal
Non Executive Director
Hooi Bien Chuah
Non Executive Director
Sylvia Lorena Varela Ramon
Executive Director
Bhavana Agrawal
Blk N1 12th Flr Manyata Embass,
Rachenahalli Outer Ring Road,
Karnataka - 560045
Tel: 91-080-67748000
Website: http://www.astrazeneca.in
Email: comp.secy@astrazeneca.com
No. 30 Ramana Resid.,
4th Cross Sampige Rd, Malleswaram,
Bangalore - 560003
Tel: 91-80-23460815-818
Website: www.integratedindia.in
Email: alfint@vsnl.com
Summary
AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates...
Read More
Reports by Astrazeneca Pharma India Ltd
What is the Astrazeneca Pharma India Ltd share price today?
What is the Market Cap of Astrazeneca Pharma India Ltd?
What is the PE and PB ratio of Astrazeneca Pharma India Ltd?
What is the 52 Week High and Low of Astrazeneca Pharma India Ltd?
What is the CAGR of Astrazeneca Pharma India Ltd?
What is the shareholding pattern of Astrazeneca Pharma India Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
